[go: up one dir, main page]

DZ3209A1 - Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. - Google Patents

Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Info

Publication number
DZ3209A1
DZ3209A1 DZ003209A DZ003209A DZ3209A1 DZ 3209 A1 DZ3209 A1 DZ 3209A1 DZ 003209 A DZ003209 A DZ 003209A DZ 003209 A DZ003209 A DZ 003209A DZ 3209 A1 DZ3209 A1 DZ 3209A1
Authority
DZ
Algeria
Prior art keywords
migraine
treatment
receptor antagonists
antagonists used
iglur5 receptor
Prior art date
Application number
DZ003209A
Other languages
English (en)
Inventor
David Bleakman
Amy Suzon Chappell
Sandra Ann Filla
Kirk Willis Johnson
Paul Leslie Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ3209A1 publication Critical patent/DZ3209A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ003209A 1999-07-06 2000-06-27 Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine. DZ3209A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27
PCT/US2000/016297 WO2001001972A2 (fr) 1999-07-06 2000-06-27 ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE

Publications (1)

Publication Number Publication Date
DZ3209A1 true DZ3209A1 (fr) 2001-01-11

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003209A DZ3209A1 (fr) 1999-07-06 2000-06-27 Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.

Country Status (28)

Country Link
US (4) US6566370B1 (fr)
EP (1) EP1200073B1 (fr)
JP (1) JP4619595B2 (fr)
KR (1) KR20020024300A (fr)
CN (1) CN1230174C (fr)
AR (1) AR029373A1 (fr)
AU (1) AU773304B2 (fr)
BR (1) BR0012175A (fr)
CA (1) CA2378613C (fr)
CZ (1) CZ20014488A3 (fr)
DE (1) DE60032905T2 (fr)
DK (1) DK1200073T3 (fr)
DZ (1) DZ3209A1 (fr)
EA (1) EA004290B1 (fr)
ES (1) ES2278619T3 (fr)
HK (1) HK1047036A1 (fr)
HR (1) HRP20020013A2 (fr)
HU (1) HUP0202253A3 (fr)
IL (1) IL146697A0 (fr)
MX (1) MXPA01012726A (fr)
MY (1) MY133503A (fr)
NO (1) NO20016246L (fr)
NZ (1) NZ515616A (fr)
PE (1) PE20010299A1 (fr)
PT (1) PT1200073E (fr)
SK (1) SK112002A3 (fr)
TR (1) TR200200066T2 (fr)
WO (1) WO2001001972A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579886B2 (en) 1999-12-22 2003-06-17 Eli Lilly And Company Selective iglur5 receptor antagonists
EP1351952A2 (fr) * 2001-01-05 2003-10-15 Eli Lilly And Company Antagonistes de recepteur d'acide amine excitateur
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
CN1484642A (zh) * 2001-01-05 2004-03-24 兴奋性氨基酸受体拮抗剂
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO2002053555A2 (fr) * 2001-01-05 2002-07-11 Eli Lilly And Company Antagonistes de recepteur d'amino acide excitateur
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
WO2003091243A1 (fr) 2002-04-26 2003-11-06 Eli Lilly And Company Derives ester d'un acide decahydroisoquinoline-3 carboxylique utiles en tant qu'analgesiques
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
EP2061465B1 (fr) 2006-08-23 2013-04-10 Valeant Pharmaceuticals International Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
BRPI0719590A2 (pt) 2006-11-28 2014-01-21 Valeant Pharmaceuticals Int Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20250048143A (ko) 2017-07-31 2025-04-07 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
EP3762414A4 (fr) 2018-03-05 2022-01-05 Janssen Pharmaceutica NV Dosages pour détecter la neurodégénérescence
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
TW202128162A (zh) 2019-11-08 2021-08-01 加拿大商再諾製藥公司 憂鬱症之治療方法
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US6242462B1 (en) * 1997-04-07 2001-06-05 Eli Lilly And Company Pharmacological agents
AU5591900A (en) * 1999-07-06 2001-01-22 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
AR029373A1 (es) 2003-06-25
EA200200132A1 (ru) 2002-06-27
NO20016246L (no) 2002-03-04
CA2378613C (fr) 2007-10-02
US6855823B2 (en) 2005-02-15
HRP20020013A2 (en) 2003-08-31
US6759418B2 (en) 2004-07-06
TR200200066T2 (tr) 2002-04-22
HUP0202253A3 (en) 2003-12-29
DE60032905T2 (de) 2007-10-18
IL146697A0 (en) 2002-07-25
JP2003503449A (ja) 2003-01-28
HK1047036A1 (zh) 2003-02-07
KR20020024300A (ko) 2002-03-29
EP1200073B1 (fr) 2007-01-10
CN1359289A (zh) 2002-07-17
US6566370B1 (en) 2003-05-20
WO2001001972A3 (fr) 2001-12-06
PT1200073E (pt) 2007-03-30
DE60032905D1 (de) 2007-02-22
BR0012175A (pt) 2002-03-05
MXPA01012726A (es) 2002-07-02
JP4619595B2 (ja) 2011-01-26
US20040192722A1 (en) 2004-09-30
WO2001001972A2 (fr) 2001-01-11
HUP0202253A2 (hu) 2002-11-28
EP1200073A2 (fr) 2002-05-02
AU5873200A (en) 2001-01-22
US20050159445A1 (en) 2005-07-21
PE20010299A1 (es) 2001-03-07
NO20016246D0 (no) 2001-12-19
EA004290B1 (ru) 2004-02-26
DK1200073T3 (da) 2007-05-07
NZ515616A (en) 2004-05-28
ES2278619T3 (es) 2007-08-16
CN1230174C (zh) 2005-12-07
US20030199546A1 (en) 2003-10-23
AU773304B2 (en) 2004-05-20
MY133503A (en) 2007-11-30
CA2378613A1 (fr) 2001-01-11
US7157582B2 (en) 2007-01-02
SK112002A3 (en) 2003-05-02
CZ20014488A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
DZ3209A1 (fr) Antagonistes selectifs du recepteur iGLuR5 utilises dans le traitement de la migraine.
DZ2618A1 (fr) Emploi des antagonistes des récepteurs de 5-HT3 dans le traitement de la colopathie.
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
MA26852A1 (fr) Agonistes selectifs du recepteur ep4 pour le traitement de l'osteoporose
EE200300246A (et) EP4 retseptori suhtes selektiivsed agonistid osteoporoosi raviks
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE60020327D1 (de) Wasserbehandlungsvorrichtung
DE60230773D1 (de) Harnstoff-derivate als vanilloid-rezeptor-antagonisten für die schmerzbehandlung
NO20011025L (no) Selektiv behandling av endoteliale somatostatinreseptorer
EP1399160A4 (fr) Antagonistes du recepteur nr2b pour le traitement ou la prevention de migraines
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
BR9809071A (pt) Agentes farmacológicos
ES1044084Y (es) Dispositivo para la limpieza de fondos de piscinas.
IS2196B (is) Blanda útskiptra bensimídasóla
DE60127712D1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
FR2814367B1 (fr) Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
MXPA03000500A (es) Uso de antagonistas del receptor de isoleucina 8 en el tratamiento de infecciones por virus.
ITMI20031433A1 (it) Apparecchio e metodo di trattamento dell'acqua potabile per la preparazione di acqua per uso topico a scopo detergente, cosmetico e/o terapeutico
EP1372630A4 (fr) Agent destine au traitement de la vessie hyperactive
ITBS20000024A0 (it) Dispositivo di intercettazione filtraggio e bilanciamento dell'acquaerogata in impianti idrosanitari
ES1044095Y (es) Dispositivo para la limpieza de fondos de piscinas.
ITRA20040027A1 (it) Sistema di filtraggio perfezionato e relativi dispositivi filtranti per la depurazione dell'acqua.
ITBS990091A0 (it) Dispositivo di intercettazione e filtraggio dell'acqua per impianti idrosanitari.